Autolus Therapeutics PLC Sponsored ADR

AUTL Healthcare Biotechnology

In the quarter to June 2026, revenue grew 118.4%, EPS grew 16.7% and free cash flow grew 67.6%, each against the same quarter a year earlier.

1.60 0.14 −8.05%
Market cap
$463.1M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−3.17
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
3.63 3.97 7.03 8.48
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(16.99) (5.62) (7.87) (6.39)
P/B ratio
5.69 3.37 2.97 1.63
Price to Tangible BV
7.56 4.09 3.35 1.77
EV/Sales
2.56 2.19 3.90 2.24
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(1.33) (0.74) (1.04) (0.45)
EV/FCF
(1.18) (0.66) (0.91) (0.37)
Quick Ratio
3.60 4.07 4.44 4.83
Current Ratio
4.89 5.80 5.94 6.19
Net Debt/EBITDA
3.04 4.06 3.37 5.34
Debt/Assets
15.76% 0.00% 11.34% 0.00%
Debt/Equity
1.04 0.00 0.38 0.00
Asset Turnover
0.19 0.15 0.11 0.07
Operating CF/Net income
0.64 0.91 0.75 0.86
Capex/Depreciation
(0.34) (1.00) 0.34 (4.92)
Interest Coverage
16.39 (5.35) (3.17) (6.81)
Research and Development Expense of Revenue
61.06% 80.90% 146.70% 131.60%
Selling, General and Administrative Expense of Revenue
90.09% 152.39% 147.36% 171.18%
Intangible Assets out of Total Assets
0.04 0.04 0.03 0.03
Share Based Compensation of Revenue
10.06% 13.60% 14.18% 18.09%
Graham Net Nets
(0.19) (0.13) 0.05 0.27
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(66.25%) (78.99%) (54.27%) (50.92%)
Free Cash Flow Yield
(59.62%) (83.85%) (61.13%) (70.72%)
Revenue per Share
0.17 0.10 0.09 0.08
Operating CF per Share
(0.09) (0.25) (0.25) (0.26)
Capex per Share
0.00 (0.01) 0.00 (0.05)
Free Cash Flow per Share
(0.10) (0.26) (0.25) (0.30)
Cash per Share
0.76 0.87 1.14 1.39
Shareholders Equity per Share
0.28 0.41 0.67 1.00
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.28 0.41 0.67 1.00
Free Cash Flow
(25.98) (68.00) (66.44) (80.40)
Working Capital
267.30 305.24 362.48 431.51
Capital Expenditures
(0.91) (2.69) 0.89 (12.50)
Net Current Asset Value
(82.30) (49.40) 24.98 118.08
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.02 0.10 (0.04) 0.59
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
35.52 20.99 12.02 37.28
Average Payables
3.39 3.16 2.53 6.19
Average Inventory
28.69 23.94 18.67 —
Average Assets
607.10 636.70 685.90 744.72
Average Common Equity
210.65 239.97 302.73 371.21

Fold the line items

Columns are period end dates · fundamentals updated 28 Sep 2026